EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view

A Cingolani iD, A Tavelli, S De Benedittis, I Mastrorosa, C Muccini iD, T Bini, A Carraro, M Compagno, M Mazzitelli iD, M Guastavigna, M Cernuschi, C Torti und 3 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von A Cingolani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. Hauptthemen laut MEDLINE: HIV Infections, Physicians, Nurses, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences, Janssen-Cilag, MSD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Implementation level of long-acting injectable agents cabotegravir/rilpivirine (LAI CAB/RPV) for human immunodeficiency virus (HIV) treatment in Italy is still not known. The aim of this study is to identify the status of implementation of LAI CAB-RPV and its barriers. Materials and methods A cross-sectional online survey was conducted among infectious diseases (ID) physicians and nurses belonging to the ICONA network in Italy. Three validate 4-items measures were used: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM).

Results

Out of 61 ICONA centres, 38 (62%) completed the survey: 57.9% were academic centres, 42.1% were hospital-based. In total, 104 respondents were ID physicians (57.4%), 77 were nurses (42.5%); 4.5% of all PWH followed at the 38 centres started LAI CAB/RPV at time of study. Centres taking care of >1000 PWH reported 95% application of procedures for LA implementation, higher than other centres (P = 0.009). Mean score of AIM was (16.0, standard deviation, SD, 3.3), of IAM (16.0, SD 3.0) and FIM (16.0, SD 2.9). A linear correlation was found between AIM and the number of people with HIV who started LAI CAB/RPV (25–50 versus <25, coefficient of correlation [b] 2.57, 95%CI 0.91–4.60, P = 0.004), academic versus hospital-based centres (b −1.59, 95%CI −2.76–0.110044, P = 0.007) and the absence of preliminary systematic assessment of staff (b −1.98, 95%CI −3.31–0.65, P = 0.004). Implementation barriers were not significantly different according to the number of PWH/centre.

Conclusions

LAI CAB/RPV implementation was low, with a great variability according to centre size. Tailored and centre-specific interventions to address barriers and to optimize the LA treatment implementation should be designed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPhysiciansNursesAnti-HIV AgentsHumansCross-Sectional StudiesItalySurveys and QuestionnairesFemaleMaleRilpivirineInjectionsAdultAttitude of Health PersonnelMiddle AgedPyridonesDiketopiperazines

Substanzen

Anti-HIV AgentsRilpivirinecabotegravirPyridonesDiketopiperazines

Autor:innen und Institutionen

  • Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Università Cattolica S. Cuore, Roma, Italy.
  • ICONA Foundation, Milano, Italy.
  • Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
  • Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milano, Italy.
  • Infectious Diseases Unit, Policlinico Tor Vergata, Roma, Italy.

ORCID-Profile: A Cingolani, C Muccini, M Mazzitelli

Förderung

  • Gilead Sciences
  • Janssen-Cilag
  • MSD
  • ViiV Healthcare

Zitieren

APA

Cingolani, A., Tavelli, A., De Benedittis, S., Mastrorosa, I., Muccini, C., Bini, T., Carraro, A., Compagno, M., Mazzitelli, M., Guastavigna, M., Cernuschi, M., Torti, C., Antinori, A., d'Arminio Monforte, A., & ICONA Foundation Study group (2024). Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae273

Vancouver

Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, et al. Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae273

BibTeX
@article{Cingolani2024,
  author = {Cingolani, A and Tavelli, A and De Benedittis, S and Mastrorosa, I and Muccini, C and Bini, T and Carraro, A and Compagno, M and Mazzitelli, M and Guastavigna, M and Cernuschi, M and Torti, C and Antinori, A and d'Arminio Monforte, A and ICONA Foundation Study group, ICONA Foundation Study group},
  title = {Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae273}
}
Kostenlos starten →